Hemato Pub Date : 2021-12-09 DOI: 10.3390/hemato2040052

K. Thoren

引用次数: 2

The Current Understanding of and Treatment Paradigm for Newly-Diagnosed TP53-Mutated Acute Myeloid Leukemia 目前对新诊断的tp53突变急性髓系白血病的认识和治疗模式

Hemato Pub Date : 2021-12-09 DOI: 10.3390/hemato2040051

R. Shallis, M. Stahl, J. Bewersdorf, A. Zeidan

引用次数: 2

Treatment in AL Amyloidosis: Moving towards Individualized and Clone-Directed Therapy AL淀粉样变性的治疗：走向个体化和克隆导向治疗

Hemato Pub Date : 2021-12-07 DOI: 10.3390/hemato2040050

U. Hegenbart, M. Raab, S. Schönland

引用次数: 0

New Targets for PET Imaging of Myeloma 骨髓瘤PET成像的新靶点

Hemato Pub Date : 2021-12-02 DOI: 10.3390/hemato2040049

M. Revheim, C. Stokke, J. N. Nørgaard, Hilde Feiring Phillips, A. Sherwani, F. Schjesvold, James Connelly

引用次数: 2

Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis. 轻链稳定:一种改善AL淀粉样变性的治疗方法。

Hemato Pub Date : 2021-12-01 Epub Date: 2021-10-05 DOI: 10.3390/hemato2040042

Gareth J Morgan, Joel N Buxbaum, Jeffery W Kelly

引用次数: 11

KSHV/HHV8-Associated Lymphoproliferative Disorders: Lessons Learnt from People Living with HIV KSHV/HHV8相关淋巴增生性疾病：从HIV感染者身上吸取的教训

Hemato Pub Date : 2021-11-24 DOI: 10.3390/hemato2040047

M. Bower, A. Carbone

{"title":"KSHV/HHV8-Associated Lymphoproliferative Disorders: Lessons Learnt from People Living with HIV","authors":"M. Bower, A. Carbone","doi":"10.3390/hemato2040047","DOIUrl":"https://doi.org/10.3390/hemato2040047","url":null,"abstract":"In 1992, Kaposi sarcoma herpesvirus (KSHV/HHV8) was discovered and identified as the causative agent for Kaposi sarcoma. Subsequently, the presence of this virus has been detected in a number of lymphoproliferative disorders in people living with HIV (PLWH), including: KSHV-associated multicentric Castleman disease, primary effusion lymphoma, KSHV-positive diffuse large B-cell lymphoma, and germinotropic lymphoproliferative disorder. Each of these rare entities has subsequently been diagnosed in HIV-negative individuals. The recognition of some of these KSHV/HHV8-associated lymphoproliferative disorders has led to their inclusion in the WHO classification of lymphomas in 2008 and the revision of 2016; however, further revision is under way to update the classification. The relatively recent recognition of these lymphoproliferative disorders and their low incidence, particularly in the HIV-negative population, means that there is little published evidence and consensus on their clinical features and management. The publication of a new WHO classification of lymphomas should yield diagnostic clarity, providing an impetus for retrospective case series and prospective clinical trials in these KSHV/HHV8-associated lymphoproliferative disorders.","PeriodicalId":93705,"journal":{"name":"Hemato","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49492785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Alterations of Peripheral Blood T Cell Subsets following Donor Lymphocyte Infusion in Patients after Allogeneic Stem Cell Transplantation 同种异体干细胞移植患者供体淋巴细胞输注后外周血T细胞亚群的改变

Hemato Pub Date : 2021-11-22 DOI: 10.3390/hemato2040046

Ann-Kristin Schmaelter, J. Waidhauser, Dina Kaiser, Tatjana Lenskaja, Stefanie Gruetzner, R. Claus, M. Trepel, C. Schmid, A. Rank

{"title":"Alterations of Peripheral Blood T Cell Subsets following Donor Lymphocyte Infusion in Patients after Allogeneic Stem Cell Transplantation","authors":"Ann-Kristin Schmaelter, J. Waidhauser, Dina Kaiser, Tatjana Lenskaja, Stefanie Gruetzner, R. Claus, M. Trepel, C. Schmid, A. Rank","doi":"10.3390/hemato2040046","DOIUrl":"https://doi.org/10.3390/hemato2040046","url":null,"abstract":"Donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation (alloSCT) is an established method to enhance the Graft-versus-Leukemia (GvL) effect. However, alterations of cellular subsets in the peripheral blood of DLI recipients have not been studied. We investigated the changes in lymphocyte subpopulations in 16 patients receiving DLI after successful alloSCT. Up to three DLIs were applied in escalating doses, prophylactically for relapse prevention in high-risk disease (n = 5), preemptively for mixed chimerism and/or a molecular relapse/persistence (n = 8), or as part of treatment for hematological relapse (n = 3). We used immunophenotyping to measure the absolute numbers of CD4+, CD8+, NK, and CD56+ T cells and their respective subsets in patients’ peripheral blood one day before DLI (d-1) and compared the results at day + 1 and + 7 post DLI to the values before DLI. After the administration of 1 × 106 CD3+ cells/kg body weight, we observed an overall increase in the CD8+ and CD56+ T cell counts. We determined significant changes between day − 1 compared to day + 1 and day + 7 in memory and activated CD8+ subsets and CD56+ T cells. Applying a higher dose of DLI (5 × 106 CD3+ cells/kg) led to a significant increase in the overall counts and subsets of CD8+, CD4+, and NK cells. In conclusion, serial immune phenotyping in the peripheral blood of DLI recipients revealed significant changes in immune effector cells, in particular for various CD8+ T cell subtypes, indicating proliferation and differentiation.","PeriodicalId":93705,"journal":{"name":"Hemato","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46360490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Differences and Similarities in Treatment Paradigms and Goals Between AL Amyloidosis and Multiple Myeloma AL淀粉样变性与多发性骨髓瘤治疗模式及目标的异同

Hemato Pub Date : 2021-11-18 DOI: 10.3390/hemato2040045

M. Minnema, R. Oostvogels, R. Raymakers, M. Jak

{"title":"Differences and Similarities in Treatment Paradigms and Goals Between AL Amyloidosis and Multiple Myeloma","authors":"M. Minnema, R. Oostvogels, R. Raymakers, M. Jak","doi":"10.3390/hemato2040045","DOIUrl":"https://doi.org/10.3390/hemato2040045","url":null,"abstract":"Although there are similarities in the treatment paradigms between AL amyloidosis and multiple myeloma, there are also fundamental differences. A similarity is of course the use of anti-plasma cell drugs in both diseases; however, the most serious mistake a hemato-oncologist can make is to use the same treatment schedule in dosing and frequency in AL amyloidosis patients as in multiple myeloma patients. AL amyloidosis patients with >10% bone marrow plasma cell infiltration in particular are at risk of receiving a more intensive treatment than they can tolerate. This difference in dosing and frequency is true for many anti-clonal drugs, but it is most apparent in the use of high-dose melphalan and autologous stem cell transplantation. While in multiple myeloma in the age group of ≤70 years, more than 80% of patients are fit enough to receive this intensive treatment, this is the case in less than 20% of AL amyloidosis patients. A similarity is the alignment in the goal of treatment. Although in AL amyloidosis has long been recognized that the goal should be complete hematological remission, this has become more apparent in multiple myeloma in recent years. A common goal in the coming years will be to evaluate the role of minimal residual disease to improve survival in both diseases.","PeriodicalId":93705,"journal":{"name":"Hemato","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41636760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Diffusion-Weighted MRI—The Way Forward for MRI in Myeloma? 弥散加权MRI:骨髓瘤MRI的发展方向?

Hemato Pub Date : 2021-11-12 DOI: 10.3390/hemato2040044

J. Hillengass, M. Merz, R. Alberico, M. Chalian

{"title":"Diffusion-Weighted MRI—The Way Forward for MRI in Myeloma?","authors":"J. Hillengass, M. Merz, R. Alberico, M. Chalian","doi":"10.3390/hemato2040044","DOIUrl":"https://doi.org/10.3390/hemato2040044","url":null,"abstract":"Multiple myeloma and other plasma cell disorders infiltrate the bone marrow in different patterns. While some patients show a homogeneous distribution of the clonal plasma cells others present with focal accumulations, commonly called focal lesions. Novel imaging techniques can provide information on these infiltration patterns and, due to their low invasiveness, can be performed repeatedly and therefore be used for monitoring. Conventional magnetic resonance imaging (MRI) has a high sensitivity for bone marrow assessment but cannot safely differentiate between active and inactive lesions. Therefore, positron emission tomography, especially combined with computed tomography (PET/CT), has been more widely used, at least for the monitoring of treatment response. Comparative, but mostly retrospective studies, have shown that functional MRI techniques, namely diffusion-weighted imaging (DWI), which assesses the movement of water molecules, can evaluate tissue cellularity with high sensitivity, which challenges the dominance of PET/CT in treatment response assessment. This review will discuss the benefits and challenges of DWI and compare it to other available imaging techniques used in patients with monoclonal plasma cell disorders.","PeriodicalId":93705,"journal":{"name":"Hemato","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47409001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current Status of CAR-T Cell Therapy in Multiple Myeloma CAR-T细胞治疗多发性骨髓瘤的研究现状

Hemato Pub Date : 2021-10-21 DOI: 10.3390/hemato2040043

Juan Luis Reguera-Ortega, Estefanía García‐Guerrero, J. Pérez-Simón

引用次数: 2

Hemato最新文献